SG11202011927TA - Pharmaceutical composition comprising mesenchymal stem cells as effective ingredient for prevention or treatment of inflammatory disease - Google Patents
Pharmaceutical composition comprising mesenchymal stem cells as effective ingredient for prevention or treatment of inflammatory diseaseInfo
- Publication number
- SG11202011927TA SG11202011927TA SG11202011927TA SG11202011927TA SG11202011927TA SG 11202011927T A SG11202011927T A SG 11202011927TA SG 11202011927T A SG11202011927T A SG 11202011927TA SG 11202011927T A SG11202011927T A SG 11202011927TA SG 11202011927T A SG11202011927T A SG 11202011927TA
- Authority
- SG
- Singapore
- Prior art keywords
- prevention
- treatment
- pharmaceutical composition
- stem cells
- mesenchymal stem
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/51—Umbilical cord; Umbilical cord blood; Umbilical stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Virology (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pulmonology (AREA)
- Reproductive Health (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Gastroenterology & Hepatology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862680748P | 2018-06-05 | 2018-06-05 | |
| PCT/KR2019/006817 WO2019235854A1 (ko) | 2018-06-05 | 2019-06-05 | 간엽줄기세포를 유효성분으로 포함하는 염증 질환 예방 또는 치료용 약학 조성물 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202011927TA true SG11202011927TA (en) | 2020-12-30 |
Family
ID=68769796
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202011927TA SG11202011927TA (en) | 2018-06-05 | 2019-06-05 | Pharmaceutical composition comprising mesenchymal stem cells as effective ingredient for prevention or treatment of inflammatory disease |
| SG11202012124PA SG11202012124PA (en) | 2018-06-05 | 2019-06-05 | Pharmaceutical composition comprising hyaluronic acid and stem cells for treating cartilage damage-associated disease |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202012124PA SG11202012124PA (en) | 2018-06-05 | 2019-06-05 | Pharmaceutical composition comprising hyaluronic acid and stem cells for treating cartilage damage-associated disease |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20210228636A1 (zh) |
| EP (2) | EP3804736A4 (zh) |
| JP (2) | JP7343091B2 (zh) |
| KR (2) | KR20210008873A (zh) |
| CN (2) | CN112261944A (zh) |
| AU (2) | AU2019283518A1 (zh) |
| CA (2) | CA3100471A1 (zh) |
| SG (2) | SG11202011927TA (zh) |
| WO (2) | WO2019235853A1 (zh) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7343091B2 (ja) * | 2018-06-05 | 2023-09-12 | メディポスト・カンパニー・リミテッド | 軟骨損傷関連の疾患を処置するための、ヒアルロン酸及び幹細胞を含む医薬組成物 |
| KR20220152137A (ko) | 2021-05-07 | 2022-11-15 | 의료법인 성광의료재단 | 골 분화능 기능강화 중간엽 줄기세포 및 이의 용도 |
| CN113616675A (zh) * | 2021-08-23 | 2021-11-09 | 上海太安堂生物医学有限公司 | 含间充质干细胞的组合物及其在治疗退行性关节炎的应用 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003015802A1 (en) * | 2001-08-14 | 2003-02-27 | Medipost, Co., Ltd. | Composition for treatment of articular cartilage damage |
| JP2007535486A (ja) * | 2003-05-07 | 2007-12-06 | ラ ホーヤ インスティチュート フォー モレキュラー メディシン | 高分子量のヒアルロン酸を用いた内因性又は埋め込まれた又は移植された幹細胞の機能回復を促進するための方法 |
| JP2007530543A (ja) | 2004-03-22 | 2007-11-01 | オシリス セラピューティクス，インコーポレイテッド | 間葉幹細胞及びその使用法 |
| AU2005228778B2 (en) | 2004-03-31 | 2010-04-01 | Yukio Kato | Therapeutic agents and therapeutic methods for treating injured tissue |
| US8444968B2 (en) * | 2005-12-07 | 2013-05-21 | Isto Technologies, Inc. | Cartilage repair methods |
| US20070178073A1 (en) * | 2006-02-01 | 2007-08-02 | Samsung Life Public Welfare Foundation | Composition Comprising Separated or Proliferated Cells from Umbilical Cord Blood for Treating Developmental and/or Chronic Lung Disease |
| KR101569168B1 (ko) * | 2007-02-12 | 2015-11-13 | 안트로제네시스 코포레이션 | 태반 줄기세포를 이용한 염증 질환의 치료 |
| AU2008255634B2 (en) * | 2007-05-28 | 2014-06-05 | Monash University | Treatment of chronic lung disease |
| JP5728234B2 (ja) * | 2008-02-15 | 2015-06-03 | ボーン・セラピューティクス | 骨関節疾患の治療又は予防において使用するための医薬組成物 |
| WO2011126177A1 (ko) * | 2010-04-05 | 2011-10-13 | 서울대학교병원 | 인간 줄기세포의 활성을 증가시키는 방법 |
| CN103263440A (zh) * | 2013-02-08 | 2013-08-28 | 周胜利 | 从胎盘、脐带中提、制同源性间充质干细胞注射剂的方法 |
| WO2015022670A1 (en) * | 2013-08-14 | 2015-02-19 | Stempeutics Research Pvt. Ltd. | Management of osteoarthritis using pooled allogeneic mesenchymal stem cells |
| JP6173157B2 (ja) | 2013-10-02 | 2017-08-02 | 日本製薬株式会社 | Ｉｌ−１７産生抑制組成物 |
| US20170166869A1 (en) * | 2014-02-04 | 2017-06-15 | Jose Javier Lopez GONZALEZ | Biologically optimized adult mesenchymal stem cells |
| GB201410504D0 (en) * | 2014-06-12 | 2014-07-30 | Cell Therapy Ltd | Immuno-modulaltory progenitor (IMP) cell |
| BR112016030758B8 (pt) | 2014-06-30 | 2022-10-25 | Tigenix S A U | Uso de células estromais multipotentes derivadas de tecido adiposo mesenquimal |
| KR101779763B1 (ko) * | 2015-03-04 | 2017-09-19 | 메디포스트(주) | 증식력 및 분화능이 개선된 간엽줄기세포를 포함하는 폐질환 예방 또는 치료용 약학적 조성물 |
| CA2983950A1 (en) * | 2015-04-24 | 2016-10-27 | Tigenix S.A.U. | Biomarkers for determining the clinical response to cell therapy |
| CN104840486A (zh) * | 2015-04-30 | 2015-08-19 | 北京益诺勤生物技术有限公司 | 一种组合物及其应用、制剂 |
| HUP1500218A2 (hu) * | 2015-05-08 | 2016-11-28 | Deltabio 2000 Kft | Eljárás és készítmény ortopédiai betegségek, így ízületiporc-sérülések, különösen ízületi diszplázia kezelésére |
| EP3097922A1 (fr) | 2015-05-28 | 2016-11-30 | Denis Barritault | Composition pour le traitement des lesions tissulaires |
| AU2017225902B2 (en) * | 2016-02-29 | 2022-12-22 | Magellan Stem Cells Pty Ltd | Methods of treatment |
| CN105796600B (zh) * | 2016-04-28 | 2020-02-28 | 博雅干细胞科技有限公司 | 使用干细胞治疗骨关节炎的方法和组合物 |
| US20180021380A1 (en) * | 2016-07-21 | 2018-01-25 | Sungkwang Medical Foundation | Composition including mesenchymal stem cell derived from adipose tissues and hyaluronic acid derivative, method of preparing the same, and method of preventing or treating low back pain using the same |
| JP7179723B2 (ja) * | 2016-10-24 | 2022-11-29 | ユナイテッド セラピューティクス コーポレイション | トレプロスチニルによるｍｓｃの免疫調節特性の増強 |
| WO2018083700A1 (en) * | 2016-11-03 | 2018-05-11 | Exostem Biotec Ltd. | Mesenchymal stem cells populations, their products, and use thereof |
| WO2018185584A1 (en) * | 2017-04-05 | 2018-10-11 | Pluristem Ltd. | Methods and compositions for treating acute lung injury and respiratory distress syndrome |
| JP7343091B2 (ja) * | 2018-06-05 | 2023-09-12 | メディポスト・カンパニー・リミテッド | 軟骨損傷関連の疾患を処置するための、ヒアルロン酸及び幹細胞を含む医薬組成物 |
| CN111518758A (zh) * | 2020-04-30 | 2020-08-11 | 深圳市合一康生物科技股份有限公司 | 一种用于肺病治疗的脐带间充质干细胞及其制备方法 |
| CN113018317A (zh) * | 2021-02-03 | 2021-06-25 | 上海兰天生物医药科技有限公司 | 间充质干细胞联合玻璃酸钠在治疗关节炎中的应用 |
-
2019
- 2019-06-05 JP JP2020564727A patent/JP7343091B2/ja active Active
- 2019-06-05 KR KR1020207036318A patent/KR20210008873A/ko not_active Application Discontinuation
- 2019-06-05 US US16/972,118 patent/US20210228636A1/en active Pending
- 2019-06-05 US US16/972,373 patent/US20210228637A1/en active Pending
- 2019-06-05 CA CA3100471A patent/CA3100471A1/en active Pending
- 2019-06-05 EP EP19815851.1A patent/EP3804736A4/en active Pending
- 2019-06-05 CN CN201980038790.3A patent/CN112261944A/zh active Pending
- 2019-06-05 JP JP2020564579A patent/JP7480454B2/ja active Active
- 2019-06-05 SG SG11202011927TA patent/SG11202011927TA/en unknown
- 2019-06-05 SG SG11202012124PA patent/SG11202012124PA/en unknown
- 2019-06-05 AU AU2019283518A patent/AU2019283518A1/en active Pending
- 2019-06-05 CA CA3100466A patent/CA3100466A1/en active Pending
- 2019-06-05 WO PCT/KR2019/006816 patent/WO2019235853A1/ko unknown
- 2019-06-05 AU AU2019283517A patent/AU2019283517A1/en active Pending
- 2019-06-05 EP EP19814590.6A patent/EP3811951A4/en active Pending
- 2019-06-05 KR KR1020207036315A patent/KR20210008101A/ko not_active Application Discontinuation
- 2019-06-05 WO PCT/KR2019/006817 patent/WO2019235854A1/ko unknown
- 2019-06-05 CN CN201980038809.4A patent/CN112261943A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN112261944A (zh) | 2021-01-22 |
| JP2021526135A (ja) | 2021-09-30 |
| WO2019235853A1 (ko) | 2019-12-12 |
| JP7343091B2 (ja) | 2023-09-12 |
| AU2019283518A1 (en) | 2021-01-14 |
| US20210228637A1 (en) | 2021-07-29 |
| US20210228636A1 (en) | 2021-07-29 |
| KR20210008101A (ko) | 2021-01-20 |
| EP3804736A1 (en) | 2021-04-14 |
| JP2021526137A (ja) | 2021-09-30 |
| CA3100471A1 (en) | 2019-12-12 |
| CN112261943A (zh) | 2021-01-22 |
| WO2019235854A1 (ko) | 2019-12-12 |
| EP3811951A1 (en) | 2021-04-28 |
| JP7480454B2 (ja) | 2024-05-10 |
| EP3804736A4 (en) | 2022-03-30 |
| CA3100466A1 (en) | 2019-12-12 |
| KR20210008873A (ko) | 2021-01-25 |
| AU2019283517A1 (en) | 2021-01-21 |
| EP3811951A4 (en) | 2022-07-13 |
| SG11202012124PA (en) | 2021-01-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202004025B (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of diseases | |
| SG11202106160WA (en) | Pharmaceutical composition for prevention or treatment of cancer comprising weissella cibaria wikim28 as active ingredient | |
| IL288375A (en) | New compounds and their pharmaceutical preparations for the treatment of diseases | |
| EP3586853A4 (en) | PHARMACEUTICAL COMPOSITION CONSISTING OF MESENCHYMATIC STEM CELL STIMULATED BY INFLAMMATION FOR THE PREVENTION OR TREATMENT OF IMMUNE OR INFLAMMATORY DISEASE | |
| ZA202002166B (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders | |
| IL279397A (en) | New compounds and their pharmaceutical preparations for the treatment of diseases | |
| SG11202011927TA (en) | Pharmaceutical composition comprising mesenchymal stem cells as effective ingredient for prevention or treatment of inflammatory disease | |
| IL286688A (en) | New compounds and their pharmaceutical preparations for the treatment of inflammatory disorders | |
| IL286677A (en) | New compounds and their pharmaceutical preparations for the treatment of inflammatory disorders | |
| GB201907558D0 (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of diseases | |
| GB201911868D0 (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders | |
| IL257336B (en) | Pharmaceutical compounds and preparations for the prevention or treatment of parasitic diseases | |
| MX2021003643A (es) | Derivados de terpenoides y usos de los mismos. | |
| EP3643302C0 (en) | COMPOSITION WITH SESQUITERPENDERIVATE AS AN ACTIVE INGREDIENT FOR THE PREVENTION OR TREATMENT OF MUSCLE DISEASES | |
| EP3603656A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF GYNECOLOGICAL DISEASES WITH EXTRACT OF SARCODON IMBRICATUS AS THE ACTIVE SUBSTANCE | |
| SG11202106163RA (en) | Pharmaceutical composition for prevention or treatment of cancer comprising lactobacillus sakei wikim30 as active ingredient | |
| IL285751A (en) | New compounds and their pharmaceutical preparations for the treatment of diseases | |
| IL286685A (en) | New compounds and their pharmaceutical preparations for the treatment of inflammatory disorders | |
| KR102324922B9 (ko) | 오스테오칼신을 포함하는 염증성 질환의 예방 또는 치료용 약학 조성물 | |
| EP3795170C0 (en) | PHARMACEUTICAL COMPOSITION COMPRISING CCN5 USED AS AN EFFECTIVE INGREDIENT FOR THE PREVENTION OR TREATMENT OF RETINAL DISEASE | |
| RS61747B1 (sr) | Farmaceutska kompozicija za lečenje konstipacije | |
| EP3903803A4 (en) | PHARMACEUTICAL COMPOSITION WITH PIBF PROTEIN AS AN ACTIVE INGREDIENT FOR THE PREVENTION OR TREATMENT OF AN INFLAMMATORY DISEASE | |
| EP3187179A4 (en) | Pharmaceutical composition for prophylaxis and/or treatment of corneal and conjunctival diseases or presbyopia containing stilbene compound as active ingredient | |
| GB201817344D0 (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of diseases | |
| GB201817343D0 (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of diseases |